Laboratory of Renal Carcinoma, Ningbo Urology and Nephrology Hospital, Urology and Nephrology Institute of Ningbo University, No.998 North Qianhe Road, Yinzhou District, Ningbo, 315100, Zhejiang, China.
School of Medicine, Shanghai Jiao Tong University, Shanghai, 200240, China.
Sci Rep. 2024 Aug 30;14(1):20150. doi: 10.1038/s41598-024-70897-3.
SHC1 plays a crucial regulatory role in various tumors, but its significance in predicting prognosis and immune response in clear cell renal cell carcinoma (ccRCC) is yet to be determined. In this study, we conducted a bioinformatics analysis of SHC1 expression, prognosis, and immunological functions in ccRCC using multiple databases. The association between SHC1 and immune infiltration, immune escape, and immunotherapy in ccRCC was systematically established. In addition, we validated our results by western blot of tumor and adjacent-tumor samples from nine ccRCC patients, as well as three renal carcinoma cell lines compared to a normal renal cell line. Our analysis revealed that the mRNA expression level of SHC1 in ccRCC tissues is significantly higher than that in normal tissues. Consistently, western blot experiment showed ccRCC tissues and cell lines exhibit higher protein levels that normal tissues and cell lines. Importantly, patients with low expression of SHC1 demonstrated a higher survival rate, indicating that SHC1 could serve as an independent prognostic factor for predicting survival in ccRCC. Additionally, high expression of SHC1 was associated with increased severe immune cell infiltration, enhanced immune escape, and higher immunotherapy scores. Hence, SHC1 emerges as a novel and easily detectable biomarker for predicting clinical outcomes, immune escape, and immunotherapy response in patients with ccRCC.
SHC1 在多种肿瘤中发挥着关键的调节作用，但它在预测透明细胞肾细胞癌（ccRCC）预后和免疫反应中的意义尚未确定。在这项研究中，我们使用多个数据库对 SHC1 在 ccRCC 中的表达、预后和免疫功能进行了生物信息学分析。系统地建立了 SHC1 与 ccRCC 中免疫浸润、免疫逃逸和免疫治疗的关联。此外，我们通过对 9 名 ccRCC 患者的肿瘤和相邻组织样本以及与正常肾细胞系相比的三种肾癌细胞系的 Western blot 验证了我们的结果。我们的分析表明，ccRCC 组织中 SHC1 的 mRNA 表达水平明显高于正常组织。Western blot 实验同样显示，ccRCC 组织和细胞系的蛋白水平高于正常组织和细胞系。重要的是，SHC1 低表达的患者具有更高的生存率，这表明 SHC1 可以作为预测 ccRCC 患者生存的独立预后因素。此外，SHC1 的高表达与严重的免疫细胞浸润增加、免疫逃逸增强和免疫治疗评分升高有关。因此，SHC1 成为预测 ccRCC 患者临床结局、免疫逃逸和免疫治疗反应的新型且易于检测的生物标志物。
